Jennifer has 20 years operating experience in the biopharmaceutical industry. In June of 2015, she joined Intellia Therapeutics, a company focused on developing curative medicines using the promise of CRISPR/CAS9 genome editing technology. Prior to joining Intellia, Jennifer a held a variety of business development and commercial roles supporting the rare disease business at Shire Pharmaceuticals. Before joining Shire in 2006, Jennifer held a variety of commercial roles in at Millennium Pharmaceuticals; most notably as the Product Manager for the US launch of VELCADE®.
Jennifer received her B.S. in Biology from the Massachusetts Institute of Technology, earned a Ph.D. in Developmental Biology at the Stanford University School of Medicine, and was awarded her MBA by Northeastern University.